Christopher Sheild Nabel, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Thymus Neoplasms | 2 | 2024 | 274 | 1.490 |
Why?
|
Cytosine | 5 | 2017 | 212 | 1.320 |
Why?
|
Cytidine Deaminase | 4 | 2017 | 245 | 1.260 |
Why?
|
Herpesvirus 8, Human | 6 | 2021 | 255 | 1.020 |
Why?
|
Thymoma | 1 | 2023 | 187 | 0.780 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2024 | 487 | 0.690 |
Why?
|
DNA | 5 | 2017 | 7233 | 0.680 |
Why?
|
Thymus Gland | 1 | 2024 | 1247 | 0.650 |
Why?
|
5-Methylcytosine | 4 | 2017 | 146 | 0.630 |
Why?
|
Neoplasm Transplantation | 1 | 2021 | 2014 | 0.580 |
Why?
|
DNA Modification Methylases | 1 | 2017 | 209 | 0.540 |
Why?
|
Cytarabine | 1 | 2017 | 696 | 0.490 |
Why?
|
RNA | 3 | 2013 | 2722 | 0.450 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2017 | 640 | 0.430 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2019 | 800 | 0.400 |
Why?
|
Macrophages | 1 | 2024 | 5745 | 0.330 |
Why?
|
Deamination | 3 | 2013 | 25 | 0.320 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2019 | 2276 | 0.270 |
Why?
|
Inflammation Mediators | 1 | 2014 | 1881 | 0.250 |
Why?
|
Oxidation-Reduction | 5 | 2017 | 2222 | 0.240 |
Why?
|
Neoplasms | 3 | 2024 | 22072 | 0.230 |
Why?
|
Uracil-DNA Glycosidase | 1 | 2024 | 37 | 0.230 |
Why?
|
Epigenesis, Genetic | 1 | 2017 | 3758 | 0.220 |
Why?
|
Lung Neoplasms | 4 | 2024 | 13262 | 0.220 |
Why?
|
Genome | 1 | 2011 | 1739 | 0.220 |
Why?
|
Uracil | 1 | 2024 | 207 | 0.210 |
Why?
|
Disease Models, Animal | 1 | 2021 | 18137 | 0.200 |
Why?
|
DNA Methylation | 3 | 2017 | 4373 | 0.200 |
Why?
|
Obesity | 1 | 2024 | 12922 | 0.200 |
Why?
|
Atherosclerosis | 1 | 2018 | 3517 | 0.200 |
Why?
|
Dioxygenases | 2 | 2016 | 335 | 0.190 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2017 | 3602 | 0.190 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2019 | 9276 | 0.180 |
Why?
|
Renin | 2 | 2000 | 635 | 0.180 |
Why?
|
Thoracic Neoplasms | 1 | 2023 | 266 | 0.180 |
Why?
|
Herpesviridae Infections | 2 | 2019 | 270 | 0.180 |
Why?
|
Genomic Instability | 1 | 2024 | 704 | 0.170 |
Why?
|
DNA Repair | 2 | 2024 | 2039 | 0.170 |
Why?
|
Multiple Endocrine Neoplasia Type 2a | 1 | 2019 | 40 | 0.170 |
Why?
|
Proto-Oncogene Proteins | 1 | 2011 | 4490 | 0.160 |
Why?
|
Cytokines | 1 | 2014 | 7343 | 0.160 |
Why?
|
Chemokines | 2 | 2024 | 962 | 0.160 |
Why?
|
Oxidoreductases Acting on CH-CH Group Donors | 1 | 2019 | 174 | 0.150 |
Why?
|
Chloride Channels | 1 | 1999 | 221 | 0.150 |
Why?
|
False Negative Reactions | 1 | 2019 | 573 | 0.150 |
Why?
|
Lymph Nodes | 3 | 2019 | 3486 | 0.150 |
Why?
|
Adrenalectomy | 1 | 2019 | 348 | 0.140 |
Why?
|
DNA Replication | 1 | 2024 | 1412 | 0.140 |
Why?
|
Angiotensin II | 1 | 1999 | 849 | 0.140 |
Why?
|
Genomics | 1 | 2011 | 5794 | 0.130 |
Why?
|
Teaching Rounds | 1 | 2020 | 275 | 0.130 |
Why?
|
Genome, Viral | 1 | 2019 | 658 | 0.130 |
Why?
|
Biocatalysis | 1 | 2016 | 172 | 0.130 |
Why?
|
Interleukin-6 | 3 | 2021 | 3215 | 0.130 |
Why?
|
Mice | 8 | 2024 | 81208 | 0.120 |
Why?
|
Gene Expression Regulation | 2 | 2011 | 11903 | 0.120 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2019 | 421 | 0.120 |
Why?
|
Plasma | 1 | 2018 | 584 | 0.120 |
Why?
|
Single-Cell Analysis | 2 | 2024 | 2380 | 0.120 |
Why?
|
Humans | 29 | 2024 | 760621 | 0.120 |
Why?
|
Nuclear Receptor Co-Repressor 1 | 1 | 2013 | 28 | 0.110 |
Why?
|
DNA-Binding Proteins | 1 | 2011 | 9585 | 0.110 |
Why?
|
Cystectomy | 1 | 2019 | 697 | 0.110 |
Why?
|
Herpesvirus 4, Human | 1 | 2019 | 1075 | 0.110 |
Why?
|
Animals | 12 | 2024 | 167963 | 0.110 |
Why?
|
Virus Diseases | 1 | 2019 | 720 | 0.110 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2019 | 608 | 0.110 |
Why?
|
RNA, Ribosomal, 18S | 1 | 2012 | 57 | 0.100 |
Why?
|
Plasma Cells | 1 | 2016 | 591 | 0.100 |
Why?
|
DNA, Viral | 1 | 2019 | 2194 | 0.100 |
Why?
|
Thrombocytopenia | 2 | 2016 | 1174 | 0.100 |
Why?
|
Interleukin-1beta | 1 | 2018 | 998 | 0.100 |
Why?
|
Sirolimus | 1 | 2019 | 1547 | 0.100 |
Why?
|
Thymine DNA Glycosylase | 1 | 2011 | 8 | 0.100 |
Why?
|
Immunotherapy | 2 | 2024 | 4642 | 0.100 |
Why?
|
Eukaryota | 1 | 2012 | 100 | 0.100 |
Why?
|
Proteomics | 3 | 2021 | 3817 | 0.090 |
Why?
|
Cell Line, Tumor | 3 | 2024 | 16939 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2019 | 2448 | 0.090 |
Why?
|
Viral Regulatory and Accessory Proteins | 1 | 2011 | 153 | 0.090 |
Why?
|
Cerebrovascular Disorders | 1 | 1997 | 1501 | 0.090 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2019 | 2058 | 0.090 |
Why?
|
Prostatectomy | 1 | 2019 | 1956 | 0.090 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2019 | 2864 | 0.090 |
Why?
|
Viral Matrix Proteins | 1 | 2011 | 197 | 0.080 |
Why?
|
Histone Deacetylases | 1 | 2013 | 718 | 0.080 |
Why?
|
Methylation | 1 | 2011 | 1082 | 0.080 |
Why?
|
Ebolavirus | 1 | 2011 | 251 | 0.080 |
Why?
|
Molecular Targeted Therapy | 1 | 2019 | 2803 | 0.080 |
Why?
|
Antihypertensive Agents | 1 | 1997 | 2061 | 0.070 |
Why?
|
Immune Evasion | 1 | 2011 | 362 | 0.070 |
Why?
|
Cell Differentiation | 1 | 2024 | 11481 | 0.070 |
Why?
|
Students, Medical | 1 | 2020 | 1927 | 0.070 |
Why?
|
Hepatocytes | 1 | 2013 | 1229 | 0.070 |
Why?
|
Diagnosis, Differential | 2 | 2019 | 12965 | 0.070 |
Why?
|
Base Sequence | 2 | 2017 | 12446 | 0.070 |
Why?
|
Cell Proliferation | 1 | 2021 | 10446 | 0.060 |
Why?
|
Lipid Metabolism | 1 | 2013 | 1902 | 0.060 |
Why?
|
Adaptation, Physiological | 1 | 2011 | 1296 | 0.060 |
Why?
|
Sequence Analysis, RNA | 1 | 2012 | 2005 | 0.060 |
Why?
|
Antibodies, Monoclonal | 2 | 2018 | 9185 | 0.060 |
Why?
|
Embryonic Stem Cells | 1 | 2011 | 1262 | 0.060 |
Why?
|
Double-Blind Method | 1 | 2018 | 12427 | 0.060 |
Why?
|
Viral Proteins | 1 | 2011 | 1802 | 0.060 |
Why?
|
Histones | 1 | 2013 | 2583 | 0.050 |
Why?
|
Proteins | 1 | 2017 | 6029 | 0.050 |
Why?
|
RNA Interference | 1 | 2011 | 2846 | 0.050 |
Why?
|
RNA, Small Interfering | 1 | 2011 | 3442 | 0.050 |
Why?
|
Models, Biological | 2 | 2017 | 9467 | 0.050 |
Why?
|
Case-Control Studies | 1 | 2019 | 22053 | 0.050 |
Why?
|
Polymorphism, Genetic | 1 | 2011 | 4291 | 0.050 |
Why?
|
Molecular Sequence Data | 1 | 2013 | 17624 | 0.040 |
Why?
|
DCMP Deaminase | 1 | 2019 | 7 | 0.040 |
Why?
|
Isethionic Acid | 1 | 1999 | 4 | 0.040 |
Why?
|
Niflumic Acid | 1 | 1999 | 10 | 0.040 |
Why?
|
Mice, Knockout | 2 | 2013 | 14372 | 0.040 |
Why?
|
Glycolates | 1 | 1999 | 40 | 0.040 |
Why?
|
Signal Transduction | 2 | 2021 | 23376 | 0.040 |
Why?
|
Transcription, Genetic | 1 | 2013 | 7593 | 0.040 |
Why?
|
Internship and Residency | 1 | 2020 | 5870 | 0.040 |
Why?
|
Sodium-Potassium-Chloride Symporters | 1 | 1999 | 104 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-sis | 1 | 2000 | 256 | 0.040 |
Why?
|
Bumetanide | 1 | 1999 | 96 | 0.040 |
Why?
|
Middle Aged | 5 | 2019 | 220352 | 0.040 |
Why?
|
Male | 10 | 2019 | 359744 | 0.040 |
Why?
|
Chemokine CXCL13 | 1 | 2018 | 59 | 0.040 |
Why?
|
Platelet-Derived Growth Factor | 1 | 2000 | 617 | 0.040 |
Why?
|
Endothelial Growth Factors | 1 | 2000 | 673 | 0.040 |
Why?
|
Liver | 1 | 2013 | 7509 | 0.040 |
Why?
|
Lymphokines | 1 | 2000 | 927 | 0.040 |
Why?
|
Hypertension | 1 | 1997 | 8594 | 0.040 |
Why?
|
Chlorides | 1 | 1999 | 663 | 0.030 |
Why?
|
HIV-1 | 1 | 2014 | 6849 | 0.030 |
Why?
|
Diuretics | 1 | 1999 | 613 | 0.030 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2000 | 1173 | 0.030 |
Why?
|
Systole | 1 | 1997 | 947 | 0.030 |
Why?
|
Human Growth Hormone | 1 | 2000 | 638 | 0.030 |
Why?
|
Research Personnel | 1 | 2020 | 582 | 0.030 |
Why?
|
Kidney | 2 | 2000 | 7064 | 0.030 |
Why?
|
Biphenyl Compounds | 1 | 2019 | 992 | 0.030 |
Why?
|
DNA Damage | 1 | 2024 | 2442 | 0.030 |
Why?
|
Nuclear Receptor Co-Repressor 2 | 1 | 2013 | 33 | 0.030 |
Why?
|
Heparin | 1 | 2001 | 1652 | 0.030 |
Why?
|
Substrate Specificity | 1 | 2017 | 1792 | 0.030 |
Why?
|
Platelet Count | 1 | 2016 | 777 | 0.030 |
Why?
|
Adult | 5 | 2019 | 219994 | 0.030 |
Why?
|
Internal Medicine | 1 | 2020 | 1048 | 0.030 |
Why?
|
Faculty, Medical | 1 | 2020 | 1192 | 0.020 |
Why?
|
Aged | 3 | 2019 | 169152 | 0.020 |
Why?
|
Molecular Structure | 1 | 2016 | 1895 | 0.020 |
Why?
|
Recombinant Proteins | 2 | 2017 | 6538 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2019 | 3584 | 0.020 |
Why?
|
Internationality | 1 | 2017 | 1004 | 0.020 |
Why?
|
Transcription Factors | 1 | 2011 | 12103 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2024 | 3844 | 0.020 |
Why?
|
Acetylation | 1 | 2013 | 1062 | 0.020 |
Why?
|
Europe | 1 | 1997 | 3441 | 0.020 |
Why?
|
Pyrimidines | 2 | 2019 | 3016 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2024 | 4550 | 0.020 |
Why?
|
Vero Cells | 1 | 2011 | 482 | 0.020 |
Why?
|
Kinetics | 1 | 2017 | 6377 | 0.020 |
Why?
|
Syndrome | 1 | 2016 | 3280 | 0.020 |
Why?
|
Rats | 3 | 2000 | 23711 | 0.020 |
Why?
|
Up-Regulation | 1 | 2018 | 4122 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 2019 | 3726 | 0.020 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2013 | 772 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 1999 | 8158 | 0.020 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2019 | 1724 | 0.020 |
Why?
|
Structure-Activity Relationship | 1 | 2013 | 3084 | 0.020 |
Why?
|
Female | 4 | 2019 | 391270 | 0.020 |
Why?
|
Fatty Liver | 1 | 2013 | 778 | 0.020 |
Why?
|
Pulmonary Embolism | 1 | 2001 | 2543 | 0.020 |
Why?
|
Virulence Factors | 1 | 2011 | 511 | 0.020 |
Why?
|
Consensus | 1 | 2017 | 3113 | 0.020 |
Why?
|
Survival Analysis | 1 | 2019 | 10182 | 0.020 |
Why?
|
Rats, Wistar | 2 | 2000 | 1850 | 0.020 |
Why?
|
Carrier Proteins | 1 | 1999 | 4938 | 0.020 |
Why?
|
Protein Conformation | 1 | 2013 | 3969 | 0.020 |
Why?
|
Feces | 1 | 2012 | 1455 | 0.020 |
Why?
|
Transfection | 1 | 2013 | 5781 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2013 | 3775 | 0.020 |
Why?
|
Biomedical Research | 1 | 2020 | 3426 | 0.010 |
Why?
|
HEK293 Cells | 1 | 2013 | 4264 | 0.010 |
Why?
|
Models, Molecular | 1 | 2013 | 5434 | 0.010 |
Why?
|
Disease Progression | 1 | 2019 | 13502 | 0.010 |
Why?
|
Adenocarcinoma | 1 | 2019 | 6315 | 0.010 |
Why?
|
Pancreatic Neoplasms | 1 | 2019 | 5351 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 1997 | 8056 | 0.010 |
Why?
|
Molsidomine | 1 | 2000 | 22 | 0.010 |
Why?
|
Receptor, Endothelin A | 1 | 2000 | 56 | 0.010 |
Why?
|
Juxtaglomerular Apparatus | 1 | 2000 | 15 | 0.010 |
Why?
|
Phenylpropionates | 1 | 2000 | 35 | 0.010 |
Why?
|
Nitric Oxide Donors | 1 | 2000 | 125 | 0.010 |
Why?
|
Thrombophlebitis | 1 | 2001 | 288 | 0.010 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2012 | 3616 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2017 | 7475 | 0.010 |
Why?
|
Hematocrit | 1 | 2000 | 629 | 0.010 |
Why?
|
Genotype | 1 | 2013 | 12960 | 0.010 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 2000 | 748 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 2000 | 11891 | 0.010 |
Why?
|
Software | 1 | 2012 | 4419 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2013 | 9411 | 0.010 |
Why?
|
Phenotype | 1 | 2013 | 16546 | 0.010 |
Why?
|
United States | 1 | 2021 | 72461 | 0.010 |
Why?
|
Reference Values | 1 | 2000 | 4925 | 0.010 |
Why?
|
Adolescent | 1 | 2019 | 87810 | 0.010 |
Why?
|
Hemodynamics | 1 | 2000 | 4174 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2000 | 3484 | 0.010 |
Why?
|
HIV Infections | 1 | 2016 | 17165 | 0.010 |
Why?
|
Young Adult | 1 | 2016 | 58741 | 0.010 |
Why?
|
Mutation | 1 | 2013 | 29932 | 0.010 |
Why?
|
Recurrence | 1 | 2001 | 8482 | 0.000 |
Why?
|
Critical Care | 1 | 2001 | 2699 | 0.000 |
Why?
|
Chronic Disease | 1 | 2000 | 9287 | 0.000 |
Why?
|
Time Factors | 1 | 2000 | 40165 | 0.000 |
Why?
|